TXTing Xu

Ting Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ting Xu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Yuan Yuan

    Department of Chemotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, China

    6 shared publications
  • Lili Zhang

    Department of Chemotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China

    3 shared publications
  • Shiyi Li

    Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China

    3 shared publications
  • Chengjun Zhu

    Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China

    2 shared publications
  • Lili Zhang

    Department of Chemotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

    2 shared publications
  • Chengjun Zhu

    Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

    1 shared publication

Latest Publications

  • Open Access

    A real-world study on treatment after TKI progression in HER2-positive MBC

    by Shiyi Li, Lili Zhang, Ting Xu, Jiayuan Huang, Chengjun Zhu, Yuan Yuan

    Background: After disease progression on anti-human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors (TKIs), trastuzumab deruxtecan (T-DXd) is recommended as a subsequent therapy. Because T-DXd has only recently been covered by insurance, patients previously opted for alternative regimens. Objectives: This study aimed to report real-world data on HER2-positive metastatic breast cancer (MBC) patients whose disease progressed during TKI therapy and provide a basis for further research. Design: This retrospective study included 216 HER2-positive MBC patients who progressed after TKI therapy between July 2014 and February 2025. Methods: All patients received anti-HER2 TKI therapy (including pyrotinib and lapatinib) in 28-day cycles. Treatment doses and combinations with chemotherapy, HER2-targeted agents, or endocrine therapy were decided by physicians. The primary objectives were to determine the proportion of patients receiving different regimens after TKI failure and evaluate progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events. Results: As of April 1, 2025, treatment distribution was 26.9% in the antibody–drug conjugate (ADC) group, 45.8% in the monoclonal antibody (mAb) group, and 27.3% in the TKI group. The expansion of ADC reimbursement under China’s healthcare policy, beginning in 2023, led to increased clinical adoption. Median PFS was 10.2 months (95% confidence interval (CI), 6.7–13.6) in the ADC group, 7.3 months (95% CI, 5.7–9.0) in the mAb group, and 7.2 months (95% CI, 5.8–8.6) in the TKI group, with no significant differences ( p = 0.282). T-DXd demonstrated substantial antitumor activity with a 12-month PFS rate of 50.0%. Patients who are acquired-resistant to TKI had better outcomes than primary-resistant ones, particularly among those continuing TKI therapy. No unexpected toxic effects were reported. Conclusion: After progression following TKI therapy, T-DXd exhibited notable antitumor activity, although no significant efficacy differences were observed among ADC, mAb, and TKI groups.

  • Open Access

    Phase II trial of anlotinib-chemotherapy combination in pretreated HER2-negative metastatic breast cancer: therapeutic efficacy and proteomic biomarker profiling

    by Ting Xu, Quan Gu, Shiyi Li, Lili Zhang, Yuan Yuan

    The management of HER2-negative metastatic breast cancer (MBC) in the second-line or later setting remains challenging, due to the absence of standardized regimens and the limited efficacy of chemotherapy. Here, we report a prospectively, single-arm, phase II study evaluating anlotinib plus chemotherapy in patients with HER2-negative MBC (n = 33) who had progressed after at least one prior line of systemic therapy for metastatic disease. The primary endpoints were median progression-free survival (mPFS) and overall survival (OS), while secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), disease control rate (DCR), and safety. Exploratory proteomic profiling using the Olink Target 96 Immuno-Oncology panel was performed on baseline serum samples to identify potential predictors of response. After a median follow-up of 25.9 months and the median number of prior systemic therapy lines was 2 (range, 1–4). The mPFS was 8.3 (95% CI: 6.3–10.3) months, and the mOS was 22.2(95% CI: 13.1–31.3) months. The ORR was 33.3%, DCR reached 90.9% and CBR stood at 60.6%. Proteomic analysis indicated that higher baseline serum levels of proteins including CSF-1 were associated with shorter PFS (P < 0.05). No treatment-related fatalities were observed. This trial is registered with www.chictr.org.cn (ChiCTR2400081835) on 13 March 2024.

  • Open Access

    Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: a multicenter real-world study

    by Shiyi Li, Ting Xu, Chengjun Zhu, Haixia Shan, Hong Xu, Jun Zhou, Lei Yang, Tongbo Yi, Xiaohong Wu, Yusong Zhang, et al.

    Background: In previous clinical trials, pyrotinib has shown good antitumor activity and manageable toxicity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). However, real-world data on pyrotinib remain limited. In this study, we reported the latest real-world data on the efficacy and safety of pyrotinib in HER2-positive MBC. Methods: This multicenter retrospective study included 337 HER2-positive MBC patients treated with pyrotinib between October 2016 and October 2024. We reported the analysis of the efficacy and safety of pyrotinib in HER2-positive MBC. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: As of April 1, 2025, the median follow-up duration was 42.6 months (range, 2.0-92.7). The median line of treatment was two. The median PFS was 15.3 months (95% CI, 12.9-17.6). By treatment line, the median PFS was 21.4 months (95% CI, 10.1-32.6) for first-line treatment, 14.8 months (95% CI, 11.4-18.1), and 10.9 months (95% CI, 8.1-13.7) for second-line and third-line or above treatment. The 3-year OS rate was 54.6% overall, with 63.2%, 61.1%, and 37.7% for first-line, second-line, and third-line or above treatment. The ORR, DCR, and CBR were 41.5%, 91.2%, and 80.0%. We further analyzed 57 patients with brain metastases (BM). The result showed that the median duration of response (DoR) and time to response (IQR) of radiotherapy-naïve ones were 12.6 months (95% CI, 6.8-18.4) and 1.7 months (95% CI, 1.3-2.2), respectively. The most frequent grade 3 or 4 adverse event was diarrhea. No treatment-related deaths were reported. Conclusion: The updated analysis demonstrated that pyrotinib could be a promising treatment option in HER2-positive MBC with acceptable toxicity in the real world. Survival is still under assessment with longer follow-up.


  • Open Access

    Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis

    by Ke Wang, Ting Xu, Jing Wu, Yuan Yuan, Xiaoxiang Guan, Chengjun Zhu

    Disitamab vedotin (RC48-ADC), an antibody-drug conjugate (ADC), combines specific antibody disitamab with cytotoxicity monomethyl auristatin E to effectively target the human epidermal growth factor receptor 2 (HER2) protein on tumor cells for precise elimination. Recent studies have demonstrated that RC48-ADC offers therapeutic benefits for patients with HER2-positive and HER2-low-expression breast cancer (BC). However, a thorough exploration of its efficacy and safety in real-world settings for patients with metastatic breast cancer (mBC) is currently lacking. This retrospective, multicenter, real-world study included patients with mBC who received RC48-ADC from September 2021 to March 2024. These patients include HER2-positive BC and HER2-low-expression BC. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), restricted mean survival time, objective response rate (ORR), and disease control rate (DCR). Factors affecting efficacy and the occurrence of treatment-related adverse events (TRAE) were evaluated. The study included a cohort of 89 patients with mBC, with 48 of those being identified as HER2-positive. As of March 2024, 22 deaths were recorded, with an immature median OS. Total PFS varied from 1.0 to 31.2 months, with a median of 5.5 months (95% CI, 4.368-6.632). HER2-positive patients exhibited prolonged PFS compared with HER2-low-expression patients (6.6 months vs 4.1 months, P = .023). The overall ORR stood at 25.8% (95% CI, 0.178-0.358), with higher rates observed in HER2-positive patients compared with HER2-low-expression patients (31.3% vs 19.5%). Similarly, the overall DCR was 78.7% (95% CI, 0.691-0.859), with HER2-positive patients demonstrating superior DCR compared with HER2-low-expression patients (83.3% vs 73.2%). Notably, HER2 expression emerged as the primary determinant of RC48-ADC efficacy. The most prevalent TRAE among all patients included leukopenia (21.3%) and alopecia (20.2%). RC48-ADC showcases promising efficacy and manageable safety in patients with both HER2-positive and HER2-low-expression mBC.


  • Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients

    by Weili Xiong, Ting Xu, Xiao Liu, Lili Zhang, Yuan Yuan

    Background: Taxanes are the basic components of breast cancer chemotherapy. Nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) shows improved antitumor effects because of more targeted delivery. However, the effects of nab‐paclitaxel have not been systematically studied in patients with metastatic breast cancer (MBC) pretreated with taxanes. Considering the limited treatment options for MBC, this study retrospectively evaluated the clinical efficacy and adverse effects of nab‐paclitaxel in patients with taxane‐pretreated MBC.Methods: Patients who had previously received taxanes and subsequently received nab‐paclitaxel chemotherapy for MBC at Jiangsu Cancer Hospital between October 2014 and April 2022 were included for analysis. The primary end point was progression‐free survival (PFS), and the secondary end points were the objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), and side effects.Results: A total of 236 female patients with MBC were included. The median PFS was 7.20 months (95% confidence interval [CI], 6.63–7.80 months), and the ORR, DCR, and CBR were 29.55% (95% CI, 23.50%–35.60%), 83.64% (95% CI, 78.70%–88.60%), and 56.36% (95% CI, 49.80%–63.00%), respectively. Following nab‐paclitaxel treatment, the median PFS of patients who were sensitive to taxanes during previous treatments was significantly longer than that of patients who were resistant to taxanes (7.57 months vs. 4.43 months, p < .001). The most common adverse events were sensory neuropathy (89.83%), neutropenia (48.73%), leukopenia (46.61%), and anemia (35.59%).Conclusion: Nab‐paclitaxel demonstrated clinical activity in taxane‐pretreated patients with MBC. This beneficial effect was observed both in patients who were sensitive and resistant to taxanes during previous treatments. These results suggest nab‐paclitaxel as the preferred chemotherapy regimen in patients with MBC, regardless of their sensitivity to taxanes during previous treatments.


  • Open Access

    The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin‐Dependent Kinase 4/6 Inhibitor in Hormone Receptor‐Positive Metastatic Breast Cancer

    by Ting Xu, Weili Xiong, Lili Zhang, Yuan Yuan

    Purpose. Endocrine therapy combined with cyclin‐dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) is the preferred treatment for hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐negative (HER2–) metastatic breast cancer (MBC). However, there are currently no recommendations for therapeutic strategies after progression on CDK4/6i‐based treatment. This study aimed to examine the efficacy and safety of anlotinib plus chemotherapy in HR+/HER2– MBC after progression on CDK4/6 inhibitors. Methods. We collected data from 32 patients with HR+/HER2– MBC treated with anlotinib plus chemotherapy after progressing on CDK4/6i at Jiangsu Cancer Hospital from March 2020 to October 2023. The median follow‐up was 9.1 months (range, 2.0–19.7 months) as of the data cutoff date in October 2023. The primary endpoint was median progression‐free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and adverse events. Results. The median PFS (mPFS) of all patients was 7.6 months (95% confidence interval (CI), 5.75–9.45). There was no significant difference in mPFS between patients who responded to prior CDK4/6i treatment and those who did not (8.3 months vs. 6.8 months, p = 0.580). Besides, the ORR was 34.4% and DCR was 93.8%. The most frequently observed adverse events were anemia (50.0%), neutropenia (40.6%), thrombocytopenia (34.4%), and epistaxis (34.4%). Dose interruption or reductions due to adverse events occurred in 2 (6.3%) and 5 (15.6%) patients, respectively. Conclusions. The study preliminarily demonstrates that anlotinib combined with chemotherapy may be an optional recommendation for patients with HR+/HER2– metastatic breast cancer who have progressed after CDK4/6i.